Blueprint Medicines said on Friday the drug regulator had put on partial hold an early stage trial testing its experimental cancer drug due to safety concerns, sending its shares down nearly 6%.
Reuters Health Information
Blueprint Medicines said on Friday the drug regulator had put on partial hold an early stage trial testing its experimental cancer drug due to safety concerns, sending its shares down nearly 6%.
Reuters Health Information
